trending Market Intelligence /marketintelligence/en/news-insights/trending/n-m4mmk5n0chgeuathwlig2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Ono Pharmaceutical secures license for antibody discovery platform

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Ono Pharmaceutical secures license for antibody discovery platform

Ono Pharmaceutical Co. Ltd. secured a global license for Ligand Pharmaceuticals' OmniAb platform to discover antibody-based treatments for diseases.

The agreement provides for the OmniRat, OmniMouse and OmniFlic platforms to formulate fully human mono- and bispecific antibodies.

Ligand will receive an undisclosed annual payment for access to the platform as well as milestone-related payments and royalty on sales of products derived from the platform.